The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.
Ulrich Herrlinger
Consultant or Advisory Role - Roche
Honoraria - Medac; Roche
Research Funding - Medac; Roche
Niklas Schaefer
No relevant relationships to disclose
Joachim Peter Steinbach
Consultant or Advisory Role - Roche
Research Funding - Merck KGaA
Astrid Weyerbrock
Consultant or Advisory Role - Roche
Peter Hau
No relevant relationships to disclose
Roland Goldbrunner
Consultant or Advisory Role - Roche
Honoraria - Roche
Franziska Friedrich
No relevant relationships to disclose
Florian Stockhammer
No relevant relationships to disclose
Florian Ringel
No relevant relationships to disclose
Christian Braun
No relevant relationships to disclose
Ralf Kohnen
No relevant relationships to disclose
Barbara Leutgeb
Employment or Leadership Position - Roche
Claus Belka
No relevant relationships to disclose
Horst Urbach
Consultant or Advisory Role - Roche
Honoraria - Roche
Walter Stummer
Consultant or Advisory Role - Roche
Martin Glas
Honoraria - Medac
Research Funding - Medac
Other Remuneration - Roche